About the Company
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 (8.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total. In 2019, the company's largest selling products were Enbrel (etanercept), a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases, and Neulasta (pegfilgrastim), an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy. Other marketed products include Evenity (romosozumab-aqqg), Otezla (apremilast), Prolia (denosumab), Repatha (evolocumab), and Lumakras (sotorasib).
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AMGN News
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 ...
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) ...
PAC Profile: Amgen Inc
*Based on data released by the Federal Election Commission on April 23, 2024 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...
Amgen CEO nabs pay raise thanks to Horizon deal. Does that incentivize aggressive M&A?
Amgen CEO Robert Bradway scored a 5.8% increase in overall compensation last year mostly thanks to the company’s acquisition ...
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Bausch + Lomb Corporation (BLCO)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN – Research Report) and Bausch ...
AMGEN Inc.
For most investors, the best investment strategy is to buy good stocks and hold them for the long run.
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® ...
Analyst Holds on Amgen’s Tezspire amid COPD Trial Uncertainties and Pending Competitor Comparisons
Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday. David Risinger has ...
More biosimilars from China, US encroach on Amgen’s denosumab
Biosimilar competition to Amgen Inc.’s denosumab (Prolia/Xgeva) is rising globally, with Mabwell (Shanghai) Bioscience Co.
Amgen Inc. (AMGN)
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected ...
Loading the latest forecasts...